Finance

Lists
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
2 246,20 INR
-0,84%
(-19,10) 1D
14 ოქტ, 09:37:17 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
2 275,00 INR
High
2 286,40 INR
Low
2 242,00 INR
Mkt. cap
634,61 მლრ.
Avg. vol.
576,02 ათ.
Volume
43,07 ათ.
Dividend
0,22%
Quarterly dividend
1,25 INR
Ex-dividend date
3 ოქტ. 2025
P/E ratio
35,27
52-wk high
2 537,60 INR
52-wk low
1 792,60 INR
EPS
63,68 INR
Shares outstanding
0,00
No. of employees
17 ათ.
Open
2 275,00 INR
High
2 286,40 INR
Low
2 242,00 INR
Mkt. cap
634,61 მლრ.
Avg. vol.
576,02 ათ.
Volume
43,07 ათ.
Dividend
0,22%
Quarterly dividend
1,25 INR
Ex-dividend date
3 ოქტ. 2025
P/E ratio
35,27
52-wk high
2 537,60 INR
52-wk low
1 792,60 INR
EPS
63,68 INR
Shares outstanding
0,00
No. of employees
17 ათ.
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16,9 ათ.
Founded1977
Headquarters-
SectorPharmaceutical industry
Websiteglenmarkpharma.com
Last report
3 აგვ. 2026
Fiscal period
Q1 2027
17,11 INR / 17,30 INR
-1,10%miss
Revenue / Est. (INR)
40,18 მლრდ. / 39,17 მლრდ.
+2,60%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
60,47 მლრდ.
39,01 მლრდ.
38,31 მლრდ.
40,18 მლრდ.
Cost of goods sold
12,65 მლრდ.
12,95 მლრდ.
13,65 მლრდ.
12,46 მლრდ.
Cost of revenue
12,65 მლრდ.
12,95 მლრდ.
13,65 მლრდ.
12,46 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,86 მლრდ.
8,41 მლრდ.
16,49 მლრდ.
9,35 მლრდ.
Operating expense
25,64 მლრდ.
18,90 მლრდ.
17,91 მლრდ.
21,41 მლრდ.
Total operating expenses
38,29 მლრდ.
31,85 მლრდ.
31,56 მლრდ.
33,87 მლრდ.
Operating income
22,18 მლრდ.
7,15 მლრდ.
6,75 მლრდ.
6,32 მლრდ.
Other non operating income
2,01 მლრდ.
444,65 მლნ.
-2,72 მლრდ.
657,64 მლნ.
EBT including unusual items
9,67 მლრდ.
5,34 მლრდ.
3,88 მლრდ.
6,43 მლრდ.
EBT excluding unusual items
23,53 მლრდ.
7,18 მლრდ.
7,61 მლრდ.
6,43 მლრდ.
Income tax expense
3,57 მლრდ.
1,31 მლრდ.
864,49 მლნ.
1,61 მლრდ.
Effective tax rate
36,90%
24,49%
22,29%
24,96%
Other operating expenses
13,37 მლრდ.
8,94 მლრდ.
-55,65 მლნ.
10,33 მლრდ.
Net income
6,10 მლრდ.
4,03 მლრდ.
3,01 მლრდ.
4,83 მლრდ.
Net profit margin
10,09%
10,34%
7,87%
12,02%
Earnings per share
-
19,21
20,96
17,11
Interest and investment income
-
-
413,36 მლნ.
-
Interest expense
-664,63 მლნ.
-414,32 მლნ.
-426,04 მლნ.
-539,97 მლნ.
Net interest expenses
-664,63 მლნ.
-414,32 მლნ.
-12,68 მლნ.
-539,97 მლნ.
Depreciation and amortization charges
1,41 მლრდ.
1,54 მლრდ.
1,48 მლრდ.
1,73 მლრდ.
EBITDA
23,54 მლრდ.
7,80 მლრდ.
7,80 მლრდ.
7,75 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები